Key Highlights

  • Basel Medical Group (NASDAQ:BMGL) traded at USD 0.5217 on November 12, 2026, down 23.73%, on about 1.06 million shares, with a Market Value near USD 7.09 million.
  • In October the company sold 6,000,000 units at USD 1.33 each, raising about USD 7.98 million gross, which lifted shares outstanding from about 1.58 million to about 7.58 million.
  • Each unit included a Warrant that can be exercised without cash for additional shares, adding up to 6,000,000 more shares of potential supply.
  • No company announcement was found for November 10 to 12, so the latest drop has no confirmed trigger.

Dilution Shapes the Share Price

Basel Medical Group (NASDAQ:BMGL) is a Singapore healthcare provider offering orthopaedic and trauma care, sports medicine, spine and neurosurgical treatment, health screening, mental health, women's health and general practice services. On October 8, 2026 it priced a registered direct offering of 6,000,000 units at USD 1.33 each, with each unit made up of one share and one common warrant, and it closed the deal on October 9 for gross proceeds of about USD 7.98 million and net proceeds of about USD 7.28 million. The offering nearly quintupled the share count, from about 1.58 million to about 7.58 million. The warrants allow a zero-cash exercise for up to 6,000,000 more shares, which means new stock can enter the market without the company receiving further cash. The stock now trades far below the offering price, and no new announcement was found for November 10 to 12, so continued selling linked to this overhang is an interpretation rather than a confirmed cause. Shareholders who bought before the offering have already absorbed a large increase in the share count.

A History of Listing Pressure

The company has spent much of 2026 managing Nasdaq requirements. It received a bid price deficiency notice in January, carried out a 1-for-12 reverse share split effective June 22, which cut shares from 18,785,750 to about 1,565,480, and regained compliance with the minimum bid rule in July. It also resolved a periodic filing deficiency in March after filing an amended annual report. At USD 0.5217, the shares are again well below USD 1.00, so a fresh deficiency notice is possible if the price remains below that level for 30 consecutive Business days. Lock-up agreements from the October deal restrict new issuance by the company and sales by insiders for 180 days, but they do not prevent warrant holders from exercising and selling. Each of these steps has added to uncertainty for investors trying to value the company.

Fundamentals and What to Watch

Trailing Revenue is about SGD 11.46 million with a net loss of about SGD 7.81 million, showing that the business is still loss-making at its current scale. The screen shows trailing diluted losses of USD 0.37 per share, an improvement of 92.79% that partly reflects the larger share count. The October proceeds strengthen the Balance Sheet and could fund clinic growth or Supply chain activity in the Asia-Pacific region. Investors should watch the pace of warrant exercises, any Nasdaq notice, interim results and how the new Capital is deployed. Until the warrant overhang clears, rallies may continue to meet selling from holders converting their warrants into shares. A clear plan for the use of proceeds would help investors assess whether the dilution has bought meaningful growth. Demand for private specialist care in Singapore offers a stable backdrop, but the company must show that added capital translates into higher patient volumes and narrower losses.

Where Things Stand

Basel Medical Group (NASDAQ:BMGL) fell 23.73% to USD 0.5217 on November 12, 2026, far below the USD 1.33 unit price of its October offering. No new announcement was found, but zero-cash warrants covering up to 6,000,000 shares and a renewed sub-dollar price keep dilution and listing risk in focus.